A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 40, 2010, Pages 17107-17112

  Doores, Katie J ^a,b,d   Fulton, Zara ^b   Hong, Vu ^b   Patel, Mitul K ^a   Scanlan, Christopher N ^c   Wormald, Mark R ^c   Finn, M G ^b   Burton, Dennis R ^b,d   Wilson, Ian A ^b   Davis, Benjamin G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

2G12; Glycoconjugate; Glycomimetic; Gp120; Oligosaccharide

Indexed keywords

CARBOHYDRATE; EPITOPE; FRUCTOSE; GLYCAN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MANNOSE; MONOCLONAL ANTIBODY 2G12; MONOSACCHARIDE; SUGAR; VIRUS GLYCOPROTEIN;

ANTIBODY TITER; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CONJUGATE; CROSS REACTION; CRYSTALLOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIGENS, VIRAL; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; EPITOPES; FRUCTOSE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; POLYSACCHARIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78049254402     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002717107     Document Type: Article

References (39)

1. AIDS Epidemic Update. Joint United Nations Programme on HIV/AIDS (United Nations, Geneva).
2. Johnson WE, Desrosiers RC (2002) Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 53:499-518.
3. Allan JS, et al. (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III/LAV. Science 228(4703):1091-1094.
4. Wyatt R, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686):705-711.
5. Saphire EO, et al. (2003) Crystal structure of an intact human IgG: Antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. Adv Exp Med Biol 535:55-66.
6. Haynes BF, et al. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
7. Zwick MB, et al. (2004) The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 78:3155-3161.
8. Cardoso RMF, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
9. Trkola A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70:1100-1108.
10. Walker L, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
11. Calarese DA, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
12. Saphire EO, et al. (2001) Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science 293:1155-1159.
13. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10:573-578.
14. Ofek G, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78:10724-10737.
15. Zhou T, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
16. Pejchal R, et al. (2009) A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83:8451-8462.
17. Scanlan CN, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 76(14):7306-7321.
18. Sanders RW, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76:7293-7305.
19. Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu Rev Biochem 57:785-838.
20. Rudd PM, Dwek RA (1997) Glycosylation: Heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol 32:1-100.
21. Weis WI (1997) Cell-surface carbohydrate recognition by animal and viral lectins. Curr Opin Struct Biol 7:624-630.
22. Wilson IA, Stanfield RL (1995) A Trojan horse with a sweet tooth. Nat Struct Biol 2:433-436.
23. Calarese DA, et al. (2005) Dissection of the carbohydrate specificity of the broadly neutralizing-anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 102:13372-13377.
24. Lee HK, et al. (2004) Reactivity-based one-pot synthesis of oligomannoses: Defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Edit 43:1000-1003.
25. Hessell AJ, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5:e1000433.
26. Astronomo RD, et al. (2008) A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 82:6359-6368.
27. Dudkin VY, et al. (2004) Toward fully synthetic carbohydrate-based HIV antigen design: On the critical role of bivalency. J Am Chem Soc 126:9560-9562.
28. Krauss IJ, et al. (2007) Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J Am Chem Soc 129:11042-11044.
29. Li H, Wang LX (2004) Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org Biomol Chem 2:483-488.
30. Ni J, Song H, Wang Y, Stamatos NM, Wang LX (2006) Toward a carbohydrate-based HIV-1 vaccine: Synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjugate Chem 17:493-500.
31. Wang LX, Ni J, Singh S, Li H (2004) Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem Biol 11:127-134.
32. Wang SK, et al. (2008) Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA 105:3690-3695.
33. Wang J, Li H, Zou G, Wang L-X (2007) Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org Biomol Chem 5:1529-1540.
34. Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons G-J (2007) Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol 3:663-667.
35. Fugedi P, Garegg PJ (1986) A novel promoter for the efficient construction of 1,2-trans linkages in glycoside synthesis, using thioglycosides as glycosyl donors. Carbohydr Res 149:C9-C12.
36. Astronomo RD, et al. (2010) Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol 17:357-370.
37. Hong V, Presolski SI, Ma C, Finn MG (2009) Analysis and optimization of copper-catalyzed azide-alkyne cycloaddition for bioconjugation. Angew Chem Int Edit 48:9879-9883.
38. Rich JR, Wakarchuk WW, Bundle DR (2006) Chemical and chemoenzymatic synthesis of S-Linked ganglioside analogues and their protein conjugates for use as immunogens. Chem Eur J 12(3):845-858.
39. Krug LM, et al. (2004) Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10(3):916-923.